NCT06453694 - Efgartigimod for the Treatment of Acute Optic Neuritis | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 31, 2024

Primary Completion Date

December 31, 2026

Study Completion Date

July 31, 2027

Conditions

Optic Neuritis

Interventions

DRUG

Efgartigimod Alfa

"2,016 mg will be administered subcutaneously by a healthcare provider on Day 0 and Day 3 of the trial.~Rescue therapy with therapeutic plasma exchange will be given to any participant based on the results of Day 7 evaluation."

DRUG

Placebo

"Subcutaneous injection of placebo will be administered by a healthcare provider on Day 0 and Day 3 of the trial.~Rescue therapy with therapeutic plasma exchange will be given to any participant based on the results of Day 7 evaluation."

Trial Locations (2)

02114

Massachusetts Eye and Ear Infirmary, Boston

Massachusetts General Hospital, Boston